ACE inhibitors have also been shown to be very effective in the prevention of HF,14,27,35,40 even more significantly in patients with left ventricular (LV) sys- tolic dysfunction or patients after MI.41,42 Likewise, ARBs have been shown to reduce the incidence of HF, espe- cially in patients with hypertension and type 2 diabetes mellitus and nephropathy.43,44 However, calcium channel blockers appear to be somewhat less efficacious than the above agents for preventing HF.8,27 There are inad- equate data to determine whether this is true only for dihydropyridine calcium channel blockers or whether it is true of the entire class of drugs.26 Regarding -blockers, in the ALLHAT trial (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial), doxazosin was inferior to chlorthalidone for the prevention of HF and was associated with the doubling of HF risk compared The 2013 ACCF/AHA Guideline for the Management of Heart Failure indicated that the role of calcium antagonists or -blockers is less clear for reducing the risk for incident HF, and the choice of antihypertensive therapy should follow the contempo- In addition to medications, patients with hypertension should be advised on healthy lifestyle modi- fication; weight reduction; reduction of sodium intake; increased consumption of fruits, vegetables, and low-fat dairy products; and moderation of alcohol intake.7,9,14 In patients with stage B HF with structural heart disease or LV dysfunction but without HF symptoms, there is benefit with ACE inhibitors, ARBs, or -blockers (Table 3). Thus, in patients with a recent or remote history of MI or acute coronary syndrome and reduced ejection fraction (EF), ACE inhibitors49 51 (or ARBs if the patient is ACE inhibitor intolerant30,52 ) prevent symptomatic HF and reduce mortality. 